

Press Release

MIG Portfolio company SuppreMol sold to Baxter for € 200 m

München, March 4th, 2015 – Baxter International Inc. (NYSE:BAX), a global, diversified healthcare company, has acquired biopharmaceutical company SuppreMol GmbH for € 200 million. Several MIG funds, advised by venture capital fund manager MIG Verwaltungs AG (MIG AG) held approximately 30 percent of SuppreMol's shares. The acquisition includes SuppreMol's early-stage development portfolio of novel biologic immunoregulatory therapeutics for the treatment of autoimmune diseases, focusing on the modulation of Fc receptor signalling pathways, an immune target that could have broad applications in autoimmune disorders. Baxter also acquires and will continue to operate SuppreMol's operations in Munich.

„MIG has been supporting SuppreMol since 2008, and we are now delighted to see our portfolio company being acquired by such a strong global player“, says Dr. Matthias Kromayer, General Partner at MIG AG and member of SuppreMol's Board. The acquisition ranks among the most important transactions within the German biotechnology industry for the last five years. „This exit will lead to substantial returns for many investors in our funds“, explains Kromayer. „At SuppreMol, we are proud to have attracted Baxter, a global leader in immunology, as a strong partner supporting the further development of our promising therapeutic programs. Based on excellent science and along with our long-standing investors, SuppreMol's team has successfully managed to realize this impressive exit“, adds Dr. Klaus Schollmeier, the company's CEO.

End

About MIG AG

MIG Verwaltungs AG (“MIG AG”) is a leading German venture capital firm managing a series of VC funds with approximately € 1.0 bn in committed capital. Investments are made in high-technology companies across a variety of development stages and industries. MIG AG's portfolio currently comprises 27 companies.

About SuppreMol

SuppreMol was founded as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize Laureate in Chemistry 1988, at the Max Planck Institute for Biochemistry in Martinsried, Germany. The company is pioneering the development of a soluble Fc-gamma receptor IIB (sFcγRIIB), which is a recombinant autologous therapeutic protein with a specific immunoregulatory potential. The company is developing this sFcγRIIB clinically for the treatment of certain autoimmune conditions including systemic lupus erythematosus (SLE). SuppreMol's preclinical pipeline includes two antibody development programs, which utilize the inhibitory effect of FcγRIIB and are suitable for alternative treatment strategies in autoimmune disease and allergy.

For further information: www.mig.ag, www.mig-fonds.de

Contact:

Dr. Matthias Kromayer
MIG Verwaltungs AG
+49-89-94382680
mk@mig.ag

Media contact:

Dr. Klaus Westermeier Medienbüro
+49-172-8433232
dr.kwest@arcor.de